Cargando…

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice

Data regarding chemotherapy options and benefits in older women with early triple-negative breast cancer (TNBC) are limited. Our study aimed to assess the effects of adjuvant chemotherapy on recurrence-free survival (RFS), breast cancer-specific survival (BCSS), and overall survival (OS) rates in el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiu, Meng, Zhang, Pin, Li, Qing, Yuan, Peng, Wang, Jiayu, Luo, Yang, Ma, Fei, Cai, Ruigang, Fan, Ying, Li, Qiao, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097590/ https://www.ncbi.nlm.nih.gov/pubmed/35574419 http://dx.doi.org/10.3389/fonc.2022.867583

Ejemplares similares

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy
por: Qian, Xiaoyan, et al.
Publicado: (2022)

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2022)

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
por: Guo, Jihong, et al.
Publicado: (2019)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population
por: Mo, Hongnan, et al.
Publicado: (2022)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
por: Xu, Hangcheng, et al.
Publicado: (2022)

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2021)

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis
por: Zhang, Jingyi, et al.
Publicado: (2020)

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making
por: Lian, Chen-Lu, et al.
Publicado: (2021)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy
por: Song, Dong, et al.
Publicado: (2021)

Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer
por: Jiang, Ke, et al.
Publicado: (2021)

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

Smog, Cognition and Real-World Decision-Making
por: Chen, Xi
Publicado: (2018)

Real-world evidence enhances decision making
por: Malone, Daniel C
Publicado: (2020)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Zhu, Meizhen, et al.
Publicado: (2021)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Timing of paclitaxel treatment in pre‐operative or post‐operative does not affect survival in breast cancer patients
por: Wang, Jiayu, et al.
Publicado: (2017)

Effectiveness of the Sanyin Formula Plus Chemotherapy on Survival in Women With Triple-Negative Breast Cancer: A Randomized Controlled Trial
por: Wu, Chunyu, et al.
Publicado: (2022)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials
por: Xu, Hangcheng, et al.
Publicado: (2022)

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
por: Di Lisa, Francesca Sofia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sr2f12ik2rr64hi0pf3cb98k2r